Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
शेयरों में रैंक #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
शेयर मूल्य
$17.15
अंतिम समन्वयन: 2026-08-03
मार्केट कैप
$6.51M
बदलाव (1 दिन)
9.80%
बदलाव (1 वर्ष)
289.77%
देश
US
व्यापार Galera Therapeutics, Inc. (GRTX)

श्रेणी

Galera Therapeutics, Inc. (GRTX) के लिए P/B अनुपात
August 2026 को P/B अनुपात TTM: 1.53
Galera Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 1.53 है। 2023 के अंत में, कंपनी का P/B अनुपात -0.05 था।
Galera Therapeutics, Inc. के लिए 2017 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
वर्ष P/B अनुपात परिवर्तन
2026 (TTM) 1.53 -7,767.00%
2024 -0.02 -64.78%
2023 -0.05 -86.64%
2022 -0.37 -81.88%
2021 -2.04 -104.91%
2020 41.59 786.53%
2019 4.69 -311.62%
2018 -2.22 -99.08%
2017 -240.04 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
कंपनी P/B अनुपात P/B अनुपात में अंतर देश
6.2613 308.33%
US
6.3483 314.00%
NL
- -
CH
- -
KR
3.634 136.99%
BE